Grifols (GRFS) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $6.41B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | ES | CEO | Jose Ignacio Abia Buenache |
| IPO Date | 2011-06-02 | CAGR | 14.02% |
| Employees | 23,833 | Website | www.grifols.com |
| Div. Yield | 8.98% | Payout Ratio | 31% |
| Buy Back Yield | 10.76% | Total Yield | 19.74% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $13.37B | P/E | 8.71 | Forward P/E | 5.25 | PEG | — |
| P/S | 0.16 | P/B | 0.22 | P/CF | 1.09 | P/FCF | 1.49 |
| Sales | $8.67B | Sales 1Y | 1.02% | Sales 3Y | 17.48% | Sales 5Y | 39.14% |
| EPS | $0.87 | EPS 1Y | 114.86% | EPS 3Y | 191.17% | EPS 5Y | -26.33% |
| Sales QoQ | -11.98% | EPS QoQ | -21.43% | Sales QoQ Avg | -0.55% | EPS QoQ Avg | 14.41% |
| Gross Margin | 37.68% | Operating Margin | 16.89% | Profit Margin | 5.58% | ROCE | 7% |
| ROA | 2% | ROE | 8% | Altman Z Score | 1.02 | Piotroski Score | 6 |
| Current Ratio | 2.47 | Quick Ratio | 0.85 | Cash Ratio | 0.33 | Op. CF Ratio | 0.05 |
| Debt/Equity | 1.77 | Debt/Assets | 0.48 | Lt Debt/Equity | 1.66 | Lt Debt/Cap. | 0.62 |
| Intrst Cov. | 2.04 | Inventory Turnover | 1.34 | Asset Turnover | 0.37 | Receivables Turnover | 7.76 |
| Enterprise Value | $13.37B | P/E Ratio | 8.71 |
| Forward P/E | 5.25 | PEG Ratio | — |
| P/S Ratio | 0.16 | P/B Ratio | 0.22 |
| P/CF Ratio | 1.09 | P/FCF Ratio | 1.49 |
| EPS | $0.87 | EPS Growth 1Y | 114.86% |
| EPS Growth 3Y | 191.17% | EPS Growth 5Y | -26.33% |
| Revenue Growth 1Y | 1.02% | Gross Margin | 0.38% |
| Operating Margin | 0.17% | Profit Margin | 0.06% |
| ROE | 0.08% | ROA | 0.02% |
| ROCE | 0.07% | Current Ratio | 2.47 |
| Quick Ratio | 0.85 | Cash Ratio | 0.33 |
| Debt/Equity | 1.77 | Interest Coverage | 2.04 |
| Altman Z Score | 1.02 | Piotroski Score | 6 |
Grifols (GRFS) valuation & financials
Grifols (GRFS) has a market capitalization of $6.41B and trades at a price-to-earnings ratio of 8.7. It operates in the Healthcare sector (Drug Manufacturers - General).
Grifols's revenue grew +1.0% over the last year.
Grifols's next earnings report is scheduled for July 28, 2026 before market open; analysts estimate EPS of $0.28.
Grifols (GRFS) — frequently asked questions
When does Grifols (GRFS) report earnings next?
Grifols is expected to report earnings on July 28, 2026 before market open. Analysts estimate EPS of $0.28.
What is Grifols's market cap?
Grifols (GRFS) has a market capitalization of $6.41B.
What is GRFS's P/E ratio?
Grifols trades at a price-to-earnings ratio of 8.7, with trailing twelve-month EPS of $0.87.
How fast is Grifols growing?
Grifols's revenue grew +1.0% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)